We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Cardiologist Care Reduces Incipient AF Mortality

By HospiMedica International staff writers
Posted on 12 Dec 2017
Specialist care associated is associated with a significantly lower death rate in patients newly diagnosed with atrial fibrillation (AF), according to a new study.

Researchers at the University of Toronto (Canada), the Institute for Clinical Evaluative Sciences (ICES; Toronto, Canada), and other institutions conducted a retrospective study of adult patients with new-onset AF in Ontario (Canada) from 2010 to 2012, in order to assess the association between cardiologist care and clinical outcomes. Patients who saw a cardiologist within one year of initial diagnosis were matched to patients who did not. Main outcomes and measures included death, hospitalization for AF, stroke syndromes, bleeding, and heart failure.

The results revealed that the majority (85%) of new-onset AF patients saw a cardiologist within the year. Cardiologist care within the first year of diagnosis was associated with a lower rate of death (5.3% versus 7.7%) than in those who did not seek care, despite increased hospitalizations for AF (17.9% versus 8.2%), stroke syndromes (1.7% versus 0.5%), bleeding (3.1% versus 2.0%), and heart failure (3.2% versus 1.4%). The results indicate that one in 15 patients with new-onset AF died within a year of the diagnosis. The study was published in the December 2017 issue of the Canadian Journal of Cardiology.

“Variations in AF care across medical specialties are well known. Other than stroke prevention therapy, no other therapy has been associated with improved survival in patients with AF,” said lead author cardiologist Sheldon Singh, MD, of the University of Toronto. “Heart failure and sudden death account for 35-50% of AF deaths, so we hypothesized that comprehensive cardiovascular care beyond stroke prevention may improve overall survival in AF patients.”

“The most startling finding from this study is the high rate of death in the cohort overall. Therefore, a new diagnosis of AF, while not immediately life-threatening, should be regarded as an important marker of near-term risk of cardiovascular events,” commented Stephen Wilton, MD, of the Libin Cardiovascular Institute of Alberta (Calgary, Canada), in an accompanying editorial. “This observation alone provides a potential rationale for desiring early cardiovascular specialist evaluation for these patients.”

AF occurs when the heart's two upper chambers beat erratically. In one form, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. It can lead to serious adverse events such as thrombi traveling from the heart to obstruct arteries supplying the brain, causing stroke, or other parts of the body causing tissue damage.

Related Links:
University of Toronto
Institute for Clinical Evaluative Sciences
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Hemostatic Agent
HEMOBLAST Bellows
New
VTE Prevention System
Flowtron ACS900

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more